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INTRODUCTION
Melioidosis is an infectious disease caused by Burkholderia pseudomallei (B.
pseudomallei), a gram- negative bacteria and bio threat agent (Mukhopadhyay,
Shaw, Varghese, & Dance, 2018). This disease is commonly found in parts of
southeast Asia and northern Australia (Chin, Monack, & Nathan, 2010). B.
pseudomallei is a facultative intracellular pathogen (Currie, 2015). B. pseudomallei is
soil associated and can be found in muddy areas such as rice paddy fields
(Krishnananthasivam et al., 2017). The rainy season contributes to the higher rates of
the disease (Lazar Adler et al., 2009). Although the bacteria may be localized, it can
be spread to organs (Lazar Adler et al., 2009). Melioidosis has a mortality rate of
around 35% (Hinjoy et al., 2018). The main way of becoming infected is through
inoculation of the skin but other routes include inhalation of aerosolized bacteria or
ingestion of contaminated water (Krishnananthasivam et al., 2017). Melioidosis can
cause an acute or chronic infection that may involve only one organ or involve many
organs progressing to septic shock (Chin et al., 2010). Septic shock could be related
to the spread of the bacteria, high mortality, and pneumonia (Wiersinga et al., 2007).
Comorbidities such as immunosuppression, diabetes mellitus, and chronic kidney
disease are greatly associated with Melioidosis (Krishnananthasivam et al., 2017).
The disease also can remain dormant for months and even years thus causing the
person to relapse (Chin et al., 2010).
OBJECTIVE
The objective of this study is to validate the gene expression markers in blood of
survivors vs. non-survivors with melioidosis that may be used for monitoring
treatment response in melioidosis. By looking at the gene alterations, they may be
used as host-based biomarkers for predicting outcomes and diagnosing melioidosis.
By using the gene expression markers in the blood, treatment response in
melioidosis may be monitored. In this transcriptomic study, whole blood from non-
survivors and survivors of melioidosis were used to analyze and compare several
differentially expressed genes Functional analysis was conducted to show the major
differentially expressed genes that are involved with the immune system’s biological
processes. The innate and adaptive immunity signaling pathways are important in
driving outcomes of melioidosis patients.
MATERIALS AND METHODS
To validate the gene expression of these markers, the total RNA was extracted from
the whole blood of patients at five hospitals in Northeast Thailand. Blood samples
were collected from 19 non-survivor and 17 survivor patients with melioidosis. The
RNA was then converted to cDNA. In this study, five genes involved in immune
system pathways TLR2, TLR4, PFKB3, RASGRP, and CD160 were selected. Three
housekeeping genes CycloA, TBP, and HPRT were also used for data analysis. The
gene expression profiles of each of the chosen immune signaling genes along with
the total RNA were then analyzed using a reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR). The data was analyzed using the Mann
Whitney Test, P-values of < 0.05 were significant.
RESULTS
CONCLUSIONS
A total of 36 patient samples were analyzed in this study of which 17 were
classified as non-survivors and 19 were classified as survivors. Five genes
were manually selected from the immune pathway analysis; three genes
were upregulated in non-survivors and two genes were downregulated in
non-survivors when compared to survivors. Using three housekeeping
genes HuP0, TBP, and HPRT were used to normalize the Cq values and
get the relative quantity. After comparing non-survivors and survivors using
the Mann-Whitney U Test, only two genes were significant (p value < 0.05).
TLR2 and TLR4 were more highly expressed in non-survivors compared to
survivors. PFKFB3, RASGRP1, and CD160 were not significant.
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Figure 2: Relative quantity of expression of genes involved in the 
immune pathway in melioidosis patients with the status of non-survivors 
compared to survivors. 
Figure 1: Location of hospitals in Northeast Thailand where samples were collected
FUTURE DIRECTIONS
This study was not to diagnose melioidosis but to build models to predict
early mortality in melioidosis. In this study, the sample size and number of
genes selected were very small. Only two genes were significant out of the
5 selected. In future studies, an increased sample size and a wider range
of genes will be used. Five genes are not enough to answer the question
so more must be observed. By looking at genes such as these, they could
predict and detect sepsis. Drugs may be developed to target and decrease
the expression of these genes and reduce the possibility of patient
mortality.
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